Skip to Main Content
TABLE 5

Hyperinsulinemic euglycemic clamp data and effects of administration of pioglitazone on hepatic glucose production and glucose uptake into skeletal muscle

Administration of pioglitazoneControls
High salt–fed rats
(−)(+)(−)(+)
n 
Plasma insulin (ng/dl) 321 ± 19 316 ± 21 337 ± 22 314 ± 37 
Blood glucose (mmol/l) 5.52 ± 0.28 5.60 ± 0.30 5.45 ± 0.24 5.49 ± 0.33 
Glucose infusion rate 23.5 ± 1.2 24.2 ± 1.0 17.1 ± 0.6* 17.6 ± 1.2 
 (mg · kg−1 · min−1
Glucose utilization rate 25.7 ± 0.9 26.3 ± 1.4 22.1 ± 0.6 22.3 ± 1.2 
 (mg · kg−1 · min−1
Hepatic glucose production 2.2 ± 0.7 2.2 ± 0.4 5.0 ± 0.7* 4.7 ± 0.6 
 (mg · kg−1 · min−1
Rg′ (muscle) 14.1 ± 1.8 13.8 ± 1.2 10.7 ± 1.2* 11.3 ± 1.8 
 (μmol · 100 g−1 · min−1
Administration of pioglitazoneControls
High salt–fed rats
(−)(+)(−)(+)
n 
Plasma insulin (ng/dl) 321 ± 19 316 ± 21 337 ± 22 314 ± 37 
Blood glucose (mmol/l) 5.52 ± 0.28 5.60 ± 0.30 5.45 ± 0.24 5.49 ± 0.33 
Glucose infusion rate 23.5 ± 1.2 24.2 ± 1.0 17.1 ± 0.6* 17.6 ± 1.2 
 (mg · kg−1 · min−1
Glucose utilization rate 25.7 ± 0.9 26.3 ± 1.4 22.1 ± 0.6 22.3 ± 1.2 
 (mg · kg−1 · min−1
Hepatic glucose production 2.2 ± 0.7 2.2 ± 0.4 5.0 ± 0.7* 4.7 ± 0.6 
 (mg · kg−1 · min−1
Rg′ (muscle) 14.1 ± 1.8 13.8 ± 1.2 10.7 ± 1.2* 11.3 ± 1.8 
 (μmol · 100 g−1 · min−1

Data are means ± SE.

*

P < 0.05.

P < 0.01 (control versus high-salt group without pioglitazone)

Close Modal

or Create an Account

Close Modal
Close Modal